Prescription Drug Dofetilide Recalled Due to Manufacturing Compliance Deviations
Accord Healthcare is recalling Dofetilide antiarrhythmic capsules due to manufacturing deviations found during an FDA inspection. The recall involves 37,790 bottles distributed across the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The manufacturing deviations represent a compliance issue identified during inspection; per the severity rubric, precautionary recalls with theoretical rather than established hazards score as Moderate (2).
Plain-English summary
Accord Healthcare, Inc. is recalling 37,790 bottles of Dofetilide antiarrhythmic capsules (125 micrograms). Dofetilide is a prescription medication used to treat abnormal heart rhythms. The product is being recalled following an FDA inspection that identified manufacturing deviations.
The FDA's inspection of the manufacturing facilities uncovered deviations from Current Good Manufacturing Practice (CGMP) standards. These deviations affect the quality assurance and manufacturing processes used to produce this medication.
The affected product was distributed throughout the United States, including Puerto Rico and Canada. Multiple batches are included in the recall, with expiration dates ranging from February 2023 through August 2025.
Patients who have this medication should contact their healthcare provider or Accord Healthcare, Inc. for guidance. Healthcare providers and pharmacies should identify affected batches in their inventory using the provided lot numbers and NDC codes. The FDA continues to monitor this situation.
The recalled product
- Product
- DOFETILIDE (DOFETILIDE)
- Brand
- DOFETILIDE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Antiarrhythmic
- Hazard
- Affected units
- 37,790
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2101480
- Exp. Date 2/28/2023
- P2102579
- P2102596
- Exp. Date 4/30/2023
- P2104711
- P2104707
- Exp. Date 6/30/2023
- P2200771
- P2200829
- P2200795
- Exp. Date 12/31/2023
- P2202608
- Exp. Date 4/30/2025
- P2203492
- P2203463
- Exp. Date 5/31/2025
- P2205373
- P2205412
- Exp. Date 8/31/2025
UPCs (1)
- 316729490122
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · DOFETILIDE
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16
- ModerateFDA Recalls Dofetilide Antiarrhythmic Drug for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighDofetilide antiarrhythmic prescription drug recalled for manufacturing deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29